Press releases

To stay up to date with our development, sign up for a subscription.


Sedana Medical publishes its Annual Report for 2022


Sedana Medical AB (publ) publishes its Annual Report for 2022. The Annual Report describes important events and financial information for 2022, as well as the progress the company has made on its strategic priorities during the year.

Sedana Medical receives market approval in Italy


Sedana Medical AB (publ) has received market approval for Sedaconda[®] (isoflurane) for inhaled sedation in intensive care in Italy, bringing the number of European countries where the company’s therapy is approved to 17.

First day of trading in Sedana Medical’s shares on Nasdaq Stockholm


Sedana Medical AB (publ) (the "Company" or "Sedana Medical") announced on 19 January 2023 that Nasdaq Stockholm's listing committee had resolved to approve the Company's application for admission to trading of the Company's shares on Nasdaq Stockholm…

Sedana Medical has been approved for trading on Nasdaq Stockholm


Nasdaq Stockholm's Listing Committee has today informed that Sedana Medical AB's (publ) (the "Company" or "Sedana Medical") application for admission to trading of the Company's shares on Nasdaq Stockholm has been approved. The approval is subject to…

Sedana Medical receives FDA Fast Track Designation in the United States


Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the evaluation of isoflurane via the Sedaconda ACD-S device for sedation of mechanically ven…